CRISPR Therapeutics
The Director will provide clinical and scientific input and medical monitoring for early-stage clinical development programs in autoimmune diseases, reporting to the VP, AID Program Leader and Head of Translational Medicine. The role is focused on clinical study oversight, review of patient data, input on trial design and execution, and presenting results to leadership and safety oversight committees.
Headquarters
Boston, Massachusetts, United States
Company Size
201-500 employees
Founded
2013
CRISPR Therapeutics is a gene-editing company pioneering the development of transformative medicines using CRISPR/Cas9 technology to treat serious diseases. The company has a broad pipeline spanning hemoglobinopathies, immuno-oncology, autoimmune diseases, in vivo editing, and regenerative medicine, including CASGEVY™, the first-ever approved CRISPR-based therapy for sickle cell disease and transfusion-dependent beta thalassemia. CRISPR Therapeutics operates across multiple clinical and preclinical programs in collaboration with partners such as Vertex Pharmaceuticals.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for CRISPR Therapeutics.
CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story
2 days ago
Late Stage Oncology Clinical Scientist (Director, Non MD) Multiple Positions
Pfizer
Senior Clinical Operations Scientist
Aurion Biotech
Medical Director, Clinical Development
Zymeworks
Clinical Scientist, Neuroimmunology
AstraZeneca
Oncology Late Stage Clinical Scientist (Senior Manager, Non MD)
Pfizer
Principal Clinical Scientist - Clinical Development
Akero Therapeutics